Esperion Therapeutics, Inc. (ESPR) Stock Analysis and Metrics

Esperion Therapeutics

NASDAQ: ESPR

$3.18 ▲ +0.00 (+0.00%)

At close: Jul 14, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap799.30 Mn

P/E-87.04

P/S1.91

Div. Yield0.00

Total Debt (Qtr)152.67 Mn

Revenue Growth (1y) (Qtr)23.25

Add ratio to table…

About

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on developing and commercializing oral medicines for patients with cardiovascular disease and elevated low density lipoprotein cholesterol. The company's lead products are NEXLETOL and NEXLIZET which are once daily tablets that do not contain a statin. These medicines are approved in the United States Europe Switzerland and other jurisdictions to lower low density lipoprotein cholesterol and to reduce the risk of major cardiovascular events in patients who cannot or will not take statin therapy. Esperion also advances a preclinical pipeline of next generation ATP citrate lyase inhibitors and pursues business development to expand its portfolio beyond the bempedoic acid franchise.

Esperion generates revenue from two main sources product sales and collaboration revenue. Product sales come from the commercial sale of NEXLETOL and NEXLIZET in the United States. Collaboration revenue consists of milestone payments royalties and sales of bulk tablets to partners outside the United States including Otsuka Pharmaceutical Co Ltd Daiichi Sankyo Europe GmbH and others. In 2025 the company recorded 159.6 million dollars in net product sales and 243.6 million dollars in collaboration revenue.

Esperion occupies a niche in the cardiovascular therapeutics market as the first company to bring an oral non statin ACLY inhibitor to patients. Its products have demonstrated both low density lipoprotein cholesterol reduction and cardiovascular risk reduction in the CLEAR Outcomes trial which showed a 13 percent reduction in major adverse cardiac events. Competitors include large pharmaceutical firms such as Amgen Pfizer and Merck that market injectable PCSK9 inhibitors as well as generic statin manufacturers and other non statins like ezetimibe. Esperion's competitive advantages stem from its novel mechanism of action its oral once daily dosing and the robust clinical evidence supporting its use in statin intolerant patients.

Esperion's customers include health care providers who prescribe its medicines pharmacies that dispense the tablets and patients who suffer from cardiovascular disease or high low density lipoprotein cholesterol and are unable or unwilling to take statin therapy. The company also works with collaboration partners such as Otsuka Pharmaceutical Co Ltd Daiichi Sankyo Europe GmbH Daiichi Sankyo Co Ltd Neopharm CSL Seqirus and HLS Therapeutics Inc which handle regulatory approval marketing and distribution in their respective territories.

Investment Thesis

▲ Bull case

The acquisition of Corstasis represents a transformative strategic move that extends Esperion's reach into the rapidly growing cardiovascular and renal therapeutic areas. With an estimated 6.7 million Americans suffering from congestive heart failure and edema as a defining clinical feature, the addressable market for Enbumyst exceeds $4 billion in the US alone, a figure that significantly surpasses the current market capitalization of Esperion. This opportunity is further amplified by the product's unique position as the first and only FDA-approved nasal spray diuretic, offering a differentiated mechanism that bypasses the gastrointestinal absorption challenges of oral diuretics and provides rapid onset of action critical for managing acute exacerbations at home. The ability to expand into hepatic and renal indications like nephrotic syndrome provides multiple growth vectors, reducing reliance on any single indication and positioning Esperion to capture value across a spectrum of chronic conditions affecting millions of patients globally. By integrating Enbumyst into its established commercial infrastructure, Esperion can leverage its existing sales force and relationships with cardiology and nephrology specialists to accelerate adoption, potentially capturing significant market share in a largely underserved space where current therapies are often limited by delayed onset or poor patient adherence due to gastrointestinal side effects.
The financial structure of the Corstasis acquisition demonstrates prudent capital allocation and minimizes near-term dilution risk. Esperion is financing the $75 million upfront payment through existing credit facilities and the monetization of its Japanese royalties via partnerships with Athyrium Capital Management and HealthCare Royalty, avoiding the need for dilutive equity offerings. This approach preserves shareholder value while providing immediate access to a revenue-generating asset with established regulatory approval. The contingent payment structure—capped at $180 million tied to regulatory and commercial milestones plus low double-digit royalties—aligns incentives between Esperion and the former Corstasis shareholders, ensuring that additional payouts are only triggered by tangible commercial success. Given the projected $4 billion market opportunity, even capturing a modest 5% share would generate $200 million in annual sales, which would comfortably cover the contingent obligations and drive meaningful accretive growth to the bottom line. This financing strategy reflects a disciplined approach to mergers and acquisitions, prioritizing balance sheet strength and avoiding over-leveraging, which is critical in the volatile biotechnology sector where access to capital can fluctuate rapidly.
The impending take-private transaction by Archimed for $1.1 billion represents a powerful external validation of Esperion's intrinsic value and future growth prospects. The offer of $3.16 per share, representing a 58% premium to the last closing price, underscores that private equity investors see substantial untapped value in the company's combined portfolio of Nexletol/Nexlizet and the newly acquired Enbumyst. This premium is particularly compelling given that Archimed's due diligence would have incorporated the full potential of the Corstasis acquisition, including the $4 billion market opportunity for Enbumyst and the synergistic cross-selling potential between cholesterol management and fluid overload therapies. The additional contingent payments of up to $100 million tied to specific sales targets—$40 million for cholesterol drug sales exceeding $350 million in 2027 and $60 million for Enbumyst reaching $160 million in sales by 2030—further validate the credibility of these projections, as the private equity firm would not structure such earn-outs without confidence in their achievability. This transaction effectively sets a floor for Esperion's valuation, signaling to the market that the company's assets are worth substantially more than its current trading range, and provides a clear pathway for shareholders to realize significant value appreciation independent of near-term market volatility.

The acquisition of Corstasis represents a transformative strategic move that extends Esperion's reach into the rapidly growing cardiovascular and renal therapeutic areas. With an estimated 6.7 million Americans suffering from congestive heart failure and edema as a defining clinical feature, the addressable market for Enbumyst exceeds $4 billion in the US alone, a figure that significantly surpasses the current market capitalization of Esperion. This opportunity is further amplified by the product's unique position as the first and only FDA-approved nasal spray diuretic, offering a differentiated mechanism that bypasses the gastrointestinal absorption challenges of oral diuretics and provides rapid onset of action critical for managing acute exacerbations at home. The ability to expand into hepatic and renal indications like nephrotic syndrome provides multiple growth vectors, reducing reliance on any single indication and positioning Esperion to capture value across a spectrum of chronic conditions affecting millions of patients globally. By integrating Enbumyst into its established commercial infrastructure, Esperion can leverage its existing sales force and relationships with cardiology and nephrology specialists to accelerate adoption, potentially capturing significant market share in a largely underserved space where current therapies are often limited by delayed onset or poor patient adherence due to gastrointestinal side effects.
The financial structure of the Corstasis acquisition demonstrates prudent capital allocation and minimizes near-term dilution risk. Esperion is financing the $75 million upfront payment through existing credit facilities and the monetization of its Japanese royalties via partnerships with Athyrium Capital Management and HealthCare Royalty, avoiding the need for dilutive equity offerings. This approach preserves shareholder value while providing immediate access to a revenue-generating asset with established regulatory approval. The contingent payment structure—capped at $180 million tied to regulatory and commercial milestones plus low double-digit royalties—aligns incentives between Esperion and the former Corstasis shareholders, ensuring that additional payouts are only triggered by tangible commercial success. Given the projected $4 billion market opportunity, even capturing a modest 5% share would generate $200 million in annual sales, which would comfortably cover the contingent obligations and drive meaningful accretive growth to the bottom line. This financing strategy reflects a disciplined approach to mergers and acquisitions, prioritizing balance sheet strength and avoiding over-leveraging, which is critical in the volatile biotechnology sector where access to capital can fluctuate rapidly.
The impending take-private transaction by Archimed for $1.1 billion represents a powerful external validation of Esperion's intrinsic value and future growth prospects. The offer of $3.16 per share, representing a 58% premium to the last closing price, underscores that private equity investors see substantial untapped value in the company's combined portfolio of Nexletol/Nexlizet and the newly acquired Enbumyst. This premium is particularly compelling given that Archimed's due diligence would have incorporated the full potential of the Corstasis acquisition, including the $4 billion market opportunity for Enbumyst and the synergistic cross-selling potential between cholesterol management and fluid overload therapies. The additional contingent payments of up to $100 million tied to specific sales targets—$40 million for cholesterol drug sales exceeding $350 million in 2027 and $60 million for Enbumyst reaching $160 million in sales by 2030—further validate the credibility of these projections, as the private equity firm would not structure such earn-outs without confidence in their achievability. This transaction effectively sets a floor for Esperion's valuation, signaling to the market that the company's assets are worth substantially more than its current trading range, and provides a clear pathway for shareholders to realize significant value appreciation independent of near-term market volatility.

▼ Bear case

The integration of Enbumyst into Esperion's commercial operations faces significant execution risks that could delay or diminish the anticipated revenue contribution. Despite the product's FDA approval in September 2025, achieving meaningful market penetration in the congestive heart failure space will require overcoming entrenched prescribing patterns among cardiologists who have relied on oral and intravenous diuretics for decades. The need to educate healthcare providers on the proper use of a novel nasal spray delivery system—including training on nasal mucosa considerations and potential adverse effects like hypovolemia and headache—could slow adoption, particularly in community practice settings where specialist involvement is limited. Furthermore, the product's label includes contraindications for patients with anuria, hepatic coma, or hypersensitivity to bumetanide, which may restrict its use in a subset of the target population, while the requirement to monitor electrolyte levels adds complexity to chronic management that could deter both physicians and patients seeking simpler therapeutic options. These adoption barriers are compounded by the competitive landscape, where established generic diuretics like furosemide and bumetanide tablets are available at a fraction of the cost, creating a significant price sensitivity barrier that may limit uptake unless payers demonstrate strong willingness to reimburse the premium-priced nasal spray.
The financial assumptions underpinning the Archimed take-private deal and the Corstasis acquisition appear optimistic and may not materialize as projected, posing a risk to the expected returns. Archimed's offer implies a valuation of approximately $1.1 billion, which assumes that Esperion's cholesterol drugs (Nexletol/Nexlizet) will achieve peak U.S. sales of $1.5 billion—a figure that seems aggressive given the competitive landscape dominated by low-cost generic statins and the recent entry of other non-statin LDL-C lowering therapies. Similarly, the expectation that Enbumyst will reach $160 million in sales by 2030 to trigger the $60 million contingent payment relies on capturing only about 4% of the purported $4 billion market opportunity, yet this assumes rapid adoption and sustained pricing power in a market where cost-effectiveness is paramount for chronic therapies. The company's full-year 2025 revenue of $403.1 million, with $168.4 million in Q4 alone, suggests a current run rate that, when annualized, falls short of the growth trajectory needed to justify the $1.1 billion valuation, raising questions about whether the underlying assumptions for both the cholesterol franchise and the new nasal spray are grounded in realistic market dynamics or reflect overly bullish projections from interested parties.
Esperion's strategic shift toward expanding into renal and hepatic indications through Enbumyst may dilute focus from its core cholesterol-lowering franchise, potentially undermining the stability of its existing revenue streams. While the company promotes the acquisition as aligned with its Vision 2040, the resources required to successfully launch and commercialize a novel therapeutic in heart failure, liver, and kidney disease—including additional sales force training, market access efforts, and pharmacovigilance monitoring—could divert attention and capital from Nexletol and Nexlizet, which currently represent the bulk of the company's revenue. This diversification risk is heightened by the fact that the renal and hepatic indications for Enbumyst, such as nephrotic syndrome, represent smaller and more complex patient populations with heterogeneous etiologies, requiring tailored approaches that may not leverage the same commercial infrastructure as the heart failure indication. Furthermore, the advancement of Corstasis's subcutaneous pipeline, including a multidose pen injector, introduces additional R&D commitments that could strain Esperion's financial resources, particularly if early-stage development fails to translate into commercial success, thereby creating a scenario where the company invests heavily in new ventures without a proportional return on investment, ultimately weakening its financial position and increasing vulnerability to market downturns in its core business.

The integration of Enbumyst into Esperion's commercial operations faces significant execution risks that could delay or diminish the anticipated revenue contribution. Despite the product's FDA approval in September 2025, achieving meaningful market penetration in the congestive heart failure space will require overcoming entrenched prescribing patterns among cardiologists who have relied on oral and intravenous diuretics for decades. The need to educate healthcare providers on the proper use of a novel nasal spray delivery system—including training on nasal mucosa considerations and potential adverse effects like hypovolemia and headache—could slow adoption, particularly in community practice settings where specialist involvement is limited. Furthermore, the product's label includes contraindications for patients with anuria, hepatic coma, or hypersensitivity to bumetanide, which may restrict its use in a subset of the target population, while the requirement to monitor electrolyte levels adds complexity to chronic management that could deter both physicians and patients seeking simpler therapeutic options. These adoption barriers are compounded by the competitive landscape, where established generic diuretics like furosemide and bumetanide tablets are available at a fraction of the cost, creating a significant price sensitivity barrier that may limit uptake unless payers demonstrate strong willingness to reimburse the premium-priced nasal spray.
The financial assumptions underpinning the Archimed take-private deal and the Corstasis acquisition appear optimistic and may not materialize as projected, posing a risk to the expected returns. Archimed's offer implies a valuation of approximately $1.1 billion, which assumes that Esperion's cholesterol drugs (Nexletol/Nexlizet) will achieve peak U.S. sales of $1.5 billion—a figure that seems aggressive given the competitive landscape dominated by low-cost generic statins and the recent entry of other non-statin LDL-C lowering therapies. Similarly, the expectation that Enbumyst will reach $160 million in sales by 2030 to trigger the $60 million contingent payment relies on capturing only about 4% of the purported $4 billion market opportunity, yet this assumes rapid adoption and sustained pricing power in a market where cost-effectiveness is paramount for chronic therapies. The company's full-year 2025 revenue of $403.1 million, with $168.4 million in Q4 alone, suggests a current run rate that, when annualized, falls short of the growth trajectory needed to justify the $1.1 billion valuation, raising questions about whether the underlying assumptions for both the cholesterol franchise and the new nasal spray are grounded in realistic market dynamics or reflect overly bullish projections from interested parties.
Esperion's strategic shift toward expanding into renal and hepatic indications through Enbumyst may dilute focus from its core cholesterol-lowering franchise, potentially undermining the stability of its existing revenue streams. While the company promotes the acquisition as aligned with its Vision 2040, the resources required to successfully launch and commercialize a novel therapeutic in heart failure, liver, and kidney disease—including additional sales force training, market access efforts, and pharmacovigilance monitoring—could divert attention and capital from Nexletol and Nexlizet, which currently represent the bulk of the company's revenue. This diversification risk is heightened by the fact that the renal and hepatic indications for Enbumyst, such as nephrotic syndrome, represent smaller and more complex patient populations with heterogeneous etiologies, requiring tailored approaches that may not leverage the same commercial infrastructure as the heart failure indication. Furthermore, the advancement of Corstasis's subcutaneous pipeline, including a multidose pen injector, introduces additional R&D commitments that could strain Esperion's financial resources, particularly if early-stage development fails to translate into commercial success, thereby creating a scenario where the company invests heavily in new ventures without a proportional return on investment, ultimately weakening its financial position and increasing vulnerability to market downturns in its core business.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Counterparty Name Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password